BridgeMD
New treatment option for Malaria Infection
Official title Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
ClinicalTrials.gov ID: NCT07038837
What this study is testing
- What it's testing
- This is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21/MM malaria vaccine, synchronized within a seasonal malaria chemoprevention (SMC) campaign, among children living in areas of high seasonal malaria transmission. In this study, a cluster is defined as the catchment area of a primary care health centre.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 59. Healthy volunteers may be eligible.
You may be able to join if
- Routine arm
- Aged 6 to 11 months at the time of the first R21/MM vaccination (dose 1).
- Residing in a village participating in the study and assigned by chance to the routine arm.
- Oral consent provided by the child's parent/guardian.
- Synchronised arm
You likely can't join if
- Exclusion criteria for both arms according to Chad national EPI guidelines Malaria vaccine is not recommended for children with known severe...
- To a previous dose of a malaria vaccine
- To a previous dose of hepatitis B vaccine
- One of the components of the R21/MM vaccine Mild illness - including respiratory tract infections, mild diarrhoea and fever below 38.5° C - is not a...
See the full eligibility criteria
- Routine arm
- Aged 6 to 11 months at the time of the first R21/MM vaccination (dose 1).
- Residing in a village participating in the study and assigned by chance to the routine arm.
- Oral consent provided by the child's parent/guardian.
- Synchronised arm
- Aged 6 to 59 months at the time of the first R21/MM vaccination (dose 1) during the first 3 rounds of SMC (2025).
- Residing in a village participating in the study and assigned by chance to the synchronized arm.
- Oral consent provided by the child's parent/guardian.
- Exclusion criteria for both arms according to Chad national EPI guidelines Malaria vaccine is not recommended for children with known severe hypersensitivity:
- To a previous dose of a malaria vaccine
- To a previous dose of hepatitis B vaccine
- One of the components of the R21/MM vaccine Mild illness - including respiratory tract infections, mild diarrhoea and fever below 38.5° C - is not a contraindication to R21/MM vaccination. Malnutrition and being...
The study team makes the final eligibility decision.
Where it's taking place
- Moïssala, Mandoul Region, Chad
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 months to 59 months. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Moïssala, Mandoul Region, Chad. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.